胃がんの世界市場レポート 2025年

胃がんの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.2％で64億3,000万米ドルに成長します。予測期間においては、肥満率の上昇、政府のイニシアチブの高まり、ヘルスケア投資の増加、経口薬の需要増、がん治療施設の拡大などにより成長が見込まれます。この期間の主な動向としては、併用化学療法、製品の拡大、協働ロボット支援手術、標的治療、戦略的提携、高度診断ツールの開発などが挙げられます。

肥満率の増加が、今後の胃がん市場の拡大を牽引すると予想されます。肥満とは、体脂肪が過剰であることを特徴とする病状であり、多くの場合、体格指数（BMI）30以上で定義され、様々な健康合併症を引き起こす可能性があります。肥満率の増加は、食生活の乱れ、運動不足、座りがちなライフスタイル、環境の影響、遺伝的要因などの要因に起因しています。過剰な体脂肪、特に腹部周辺の内臓脂肪は、胃がんの発症リスクの上昇につながります。肥満は慢性的な炎症と代謝の不均衡を引き起こし、その両方ががんの発生に関連するため、胃がん治療の需要が高まる。例えば、世界保健機関（WHO）は2024年3月、2022年には世界の約8人に1人が肥満と共存していると報告しました。18歳以上の成人の約25億人が太りすぎと考えられ、8億9,000万人が肥満と分類されました。成人の43％が太りすぎ、16％が肥満でした。さらに、5歳未満の子どもの3,700万人が太りすぎ、5～19歳の子どもと青少年の3億9,000万人以上が太りすぎで、そのうち1億6,000万人が肥満と共存しています。その結果、肥満率の上昇が胃がん治療への需要に拍車をかけています。

胃がん市場の主要企業は、個別化治療を確実にするため、コンパニオン診断アッセイなどの先進ソリューションの開発に注力しています。コンパニオン診断アッセイは、特定のバイオマーカーに基づいて特定の治療が有効である可能性の高い患者を特定する検査です。2024年10月、スイスに本社を置く製薬会社F.ホフマン・ラ・ロシュ社は、米国食品医薬品局（FDA）よりVENTANA CLDN18（43-14A）RxDx Assayの承認を取得しました。これは、胃および胃食道接合部（GEJ）腺がんにおけるCLDN18タンパク発現を評価する初めての免疫組織化学（IHC）コンパニオン診断薬です。この検査は、CLDN18タンパク質の変異体、特にCLDN18.2を検出することにより、VYLOY（ゾルベツキシマブ）による標的治療の対象となる患者を同定します。本検査はBenchMark ULTRA装置でOptiView DAB IHC検出キットを使用し、個別化ヘルスケアを推進し、胃およびGEJ腺がん患者の治療選択肢を拡大します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界胃がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胃がん市場：成長率分析
• 世界の胃がん市場の実績：規模と成長, 2019-2024
• 世界の胃がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界胃がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃がん市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腺がん
• リンパ腫
• 消化管間質腫瘍
• カルチノイド腫瘍
• その他のタイプ
• 世界の胃がん市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 内視鏡検査
• 生検
• 画像検査
• 探索手術
• その他の診断
• 世界の胃がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 化学療法
• 標的療法
• 緩和ケア
• その他の治療法
• 世界の胃がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 専門薬局および小売薬局
• その他の流通チャネル
• 世界の胃がん市場腺がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腸型腺がん
• びまん型腺がん
• 混合型腺がん
• 世界の胃がん市場リンパ腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性胃リンパ腫
• 二次性胃リンパ腫
• 世界の胃がん市場消化管間質腫瘍（GIST）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性GIST
• 転移性GIST
• 世界の胃がん市場カルチノイド腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胃カルチノイド1型
• 胃カルチノイド2型
• 胃カルチノイド3型
• 世界の胃がん市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小細胞がん
• 扁平上皮がん
• 混合腫瘍

第7章 地域別・国別分析

• 世界の胃がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃がん市場：競合情勢
• 胃がん市場：企業プロファイル
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ipsen Biopharmaceuticals Inc.
• Ono Pharmaceutical Co. Ltd.
• Samsung Biologics Co. Ltd.
• Celltrion Healthcare Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃がん市場2029：新たな機会を提供する国
• 胃がん市場2029：新たな機会を提供するセグメント
• 胃がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastric cancer is a malignant tumor that begins in the stomach lining, often starting in the mucosa, the innermost layer of the stomach. If left untreated, it can spread to deeper layers, surrounding tissues, or distant organs. Common risk factors for the disease include chronic infection with Helicobacter pylori, smoking, heavy alcohol consumption, an unhealthy diet, and genetic factors.

The main types of gastric cancers include adenocarcinoma, lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others. Adenocarcinoma, the most prevalent type, originates in the glandular cells of the stomach lining. Diagnosis is typically made through endoscopy, biopsy, imaging tests, exploratory surgery, and other methods. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, palliative care, and more. These treatments are distributed through various channels, including hospital pharmacies, specialty and retail pharmacies, among others.

The gastric cancer market research report is one of a series of new reports from The Business Research Company that provides gastric cancer market statistics, including gastric cancer industry global market size, regional shares, competitors with a gastric cancer market share, detailed gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer industry. This gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer market size has grown rapidly in recent years. It will grow from $3.17 billion in 2024 to $3.65 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth during the historic period can be attributed to factors such as an increasing geriatric population, rising healthcare awareness, a growing number of genetic mutations, the adoption of unhealthy lifestyles, and heightened awareness about cancer.

The gastric cancer market size is expected to see rapid growth in the next few years. It will grow to $6.43 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. In the forecast period, growth is expected due to rising obesity rates, growing government initiatives, increased healthcare investments, a higher demand for oral drugs, and the expanding number of cancer treatment facilities. Key trends during this period include combination chemotherapy, product expansion, robotic-assisted surgery, targeted therapies, strategic collaborations, and the development of advanced diagnostic tools.

The growing rates of obesity are expected to drive the expansion of the gastric cancer market in the future. Obesity is a medical condition characterized by excessive body fat, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health complications. The increase in obesity rates can be attributed to factors such as poor dietary habits, lack of exercise, sedentary lifestyles, environmental influences, and genetic factors. Excess body fat, especially visceral fat around the abdomen, is linked to an elevated risk of developing gastric cancer. Obesity causes chronic inflammation and metabolic imbalances, both of which are associated with cancer development, thereby contributing to a higher demand for gastric cancer treatments. For example, the World Health Organization reported in March 2024 that approximately 1 in 8 people globally were living with obesity in 2022. Around 2.5 billion adults aged 18 and older were considered overweight, with 890 million classified as obese. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 were overweight, and more than 390 million children and adolescents aged 5-19 were overweight, including 160 million living with obesity. As a result, rising obesity rates are fueling the demand for gastric cancer treatments.

Leading companies in the gastric cancer market are focused on developing advanced solutions, such as companion diagnostic assays, to ensure personalized treatment. Companion diagnostic assays are tests that identify patients likely to benefit from specific treatments based on certain biomarkers. In October 2024, F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA CLDN18 (43-14A) RxDx Assay. This was the first immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. The assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by detecting CLDN18 protein variants, particularly CLDN18.2. This test utilizes the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, advancing personalized healthcare and expanding treatment options for gastric and GEJ adenocarcinoma patients.

In June 2022, Panbela Therapeutics Inc., a US-based biopharmaceutical company, acquired Cancer Prevention Pharmaceuticals Inc. for an undisclosed amount. This acquisition allows Panbela Therapeutics to diversify its pipeline and address multiple therapeutic areas. The deal adds four clinical-stage assets, including two late-stage registration assets, enhancing the combined entity's potential. This strategic move strengthens Panbela's position in high-potential therapeutic areas. Cancer Prevention Pharmaceuticals Inc. is a biotechnology company in the US that develops therapeutics for gastric cancer treatment.

Major players in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., and AROG Pharmaceuticals Inc.

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastric cancer market consists of revenues earned by entities by providing services such as cancer screening and early detection, genetic testing, personalized treatment planning, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer market also includes sales of chemotherapeutic drugs, radiation therapy equipment, nutritional support products, surgical tools, and instruments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
• 2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis
• 3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments
• 4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma
• 2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma
• 3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST
• 4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3
• 5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors
• Companies Mentioned: F. Hoffmann La Roche Ltd.; Merck And Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastric Cancer Market Characteristics

3. Gastric Cancer Market Trends And Strategies

4. Gastric Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gastric Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastric Cancer Market Growth Rate Analysis
• 5.4. Global Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastric Cancer Total Addressable Market (TAM)

6. Gastric Cancer Market Segmentation

• 6.1. Global Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Lymphoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Other Types
• 6.2. Global Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopy
• Biopsy
• Imaging Tests
• Exploratory Surgery
• Other Diagnosis
• 6.3. Global Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Targeted Therapy
• Palliative Care
• Other Treatments
• 6.4. Global Gastric Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Specialty And Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Gastric Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intestinal Type Adenocarcinoma
• Diffuse Type Adenocarcinoma
• Mixed Type Adenocarcinoma
• 6.6. Global Gastric Cancer Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Gastric Lymphoma
• Secondary Gastric Lymphoma
• 6.7. Global Gastric Cancer Market, Sub-Segmentation Of Gastrointestinal Stromal Tumor (GIST), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary GIST
• Metastatic GIST
• 6.8. Global Gastric Cancer Market, Sub-Segmentation Of Carcinoid Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastric Carcinoid Type 1
• Gastric Carcinoid Type 2
• Gastric Carcinoid Type 3
• 6.9. Global Gastric Cancer Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Cell Carcinoma
• Squamous Cell Carcinoma
• Mixed Tumors

7. Gastric Cancer Market Regional And Country Analysis

• 7.1. Global Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastric Cancer Market

• 8.1. Asia-Pacific Gastric Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastric Cancer Market

• 9.1. China Gastric Cancer Market Overview
• 9.2. China Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastric Cancer Market

• 10.1. India Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastric Cancer Market

• 11.1. Japan Gastric Cancer Market Overview
• 11.2. Japan Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastric Cancer Market

• 12.1. Australia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastric Cancer Market

• 13.1. Indonesia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastric Cancer Market

• 14.1. South Korea Gastric Cancer Market Overview
• 14.2. South Korea Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastric Cancer Market

• 15.1. Western Europe Gastric Cancer Market Overview
• 15.2. Western Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastric Cancer Market

• 16.1. UK Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastric Cancer Market

• 17.1. Germany Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastric Cancer Market

• 18.1. France Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastric Cancer Market

• 19.1. Italy Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastric Cancer Market

• 20.1. Spain Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastric Cancer Market

• 21.1. Eastern Europe Gastric Cancer Market Overview
• 21.2. Eastern Europe Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastric Cancer Market

• 22.1. Russia Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastric Cancer Market

• 23.1. North America Gastric Cancer Market Overview
• 23.2. North America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastric Cancer Market

• 24.1. USA Gastric Cancer Market Overview
• 24.2. USA Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastric Cancer Market

• 25.1. Canada Gastric Cancer Market Overview
• 25.2. Canada Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastric Cancer Market

• 26.1. South America Gastric Cancer Market Overview
• 26.2. South America Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastric Cancer Market

• 27.1. Brazil Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastric Cancer Market

• 28.1. Middle East Gastric Cancer Market Overview
• 28.2. Middle East Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastric Cancer Market

• 29.1. Africa Gastric Cancer Market Overview
• 29.2. Africa Gastric Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastric Cancer Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastric Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastric Cancer Market Competitive Landscape And Company Profiles

• 30.1. Gastric Cancer Market Competitive Landscape
• 30.2. Gastric Cancer Market Company Profiles
  • 30.2.1. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Gastric Cancer Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline Plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Gilead Sciences Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Boehringer Ingelheim
• 31.9. Astellas Pharma Inc.
• 31.10. Daiichi Sankyo Company Limited
• 31.11. Eisai Co. Ltd.
• 31.12. Ipsen Biopharmaceuticals Inc.
• 31.13. Ono Pharmaceutical Co. Ltd.
• 31.14. Samsung Biologics Co. Ltd.
• 31.15. Celltrion Healthcare Co. Ltd.

32. Global Gastric Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastric Cancer Market

34. Recent Developments In The Gastric Cancer Market

35. Gastric Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastric Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer